Effect of zidovudine on cerebrospinal fluid in patients with HIV infection and acute neurological disease.
Two cases of HIV infection associated with neurological complications are described. The patients had been followed with repeated cerebrospinal fluid (CSF) analyses 1-3 years before the neurological disease and 5 months after zidovudine treatment. CSF mononuclear cell count and the AIDS predictors beta 2-microglobulin and neopterin decreased in CSF after treatment and were lower or at the level seen 1-3 years before treatment. The results suggest that zidovudine has a suppressive effect on the HIV infection in CNS at least for 5 months, even when low zidovudine doses (500 mg daily) were used.
Hagberg
L
L
Department of Infectious Diseases, University of Göteborg, Ostra Hospital, Sweden.
Andersson
M
M
Chiodi
F
F
Fuchs
D
D
Svennerholm
B
B
Wachter
H
H
Norkrans
G
G
D015526:AIDS Dementia Complex / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D000208:Acute Disease; D000328:Adult; D001708:Biopterins / Q000031:analogs & derivatives / Q000134:cerebrospinal fluid; D005260:Female; D015658:HIV Infections / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D006801:Humans; D007958:Leukocyte Count; D007963:Leukocytes, Mononuclear; D008297:Male; D008875:Middle Aged; D019798:Neopterin; D015215:Zidovudine / Q000134:cerebrospinal fluid / Q000627:therapeutic use*; D001613:beta 2-Microglobulin / Q000134:cerebrospinal fluid
D001613:beta 2-Microglobulin; D001708:Biopterins; D015215:Zidovudine; D019798:Neopterin